Chemed (NYSE:CHE) Releases Quarterly Earnings Results, Beats Expectations By $0.31 EPS

Chemed (NYSE:CHE) issued its quarterly earnings results on Tuesday. The company reported $6.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.44 by $0.31, FiscalAI reports. The business had revenue of $690.94 million for the quarter, compared to the consensus estimate of $685.04 million. During the same period in the prior year, the business posted $5.27 earnings per share. Chemed’s revenue was up 10.6% on a year-over-year basis.

Chemed Stock Performance

Shares of NYSE CHE opened at $506.46 on Wednesday. The firm has a market capitalization of $6.62 billion, a price-to-earnings ratio of 25.44 and a beta of 0.51. The stock has a 50 day moving average price of $514.46 and a 200 day moving average price of $461.61. Chemed has a 52-week low of $365.20 and a 52-week high of $557.00.

Chemed Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, September 3rd. Investors of record on Monday, August 17th were issued a $0.70 dividend. The ex-dividend date was Monday, August 17th. This is a positive change from Chemed’s previous quarterly dividend of $0.60. This represents a $2.80 dividend on an annualized basis and a dividend yield of 0.6%. Chemed’s dividend payout ratio (DPR) is presently 14.06%.

Analysts Set New Price Targets

CHE has been the topic of several research analyst reports. UBS Group started coverage on Chemed in a research report on Friday, September 25th. They issued a “buy” rating and a $650.00 price objective on the stock. Weiss Ratings upgraded Chemed from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Jefferies Financial Group raised shares of Chemed from a “hold” rating to a “buy” rating and set a $620.00 target price for the company in a research note on Wednesday. Royal Bank Of Canada upped their price target on shares of Chemed from $436.00 to $548.00 and gave the stock a “sector perform” rating in a report on Thursday, July 30th. Finally, Oppenheimer upped their price target on shares of Chemed from $500.00 to $590.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Three investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $583.60.

More Chemed News

Here are the key news stories impacting Chemed this week:

• Positive Sentiment: Adjusted earnings rose 28.1% year over year to $6.75 per share, exceeding the $6.44 consensus estimate, while revenue increased 10.6% to $690.9 million, ahead of expectations. Chemed Q3 Adjusted Earnings, Revenue Rise
• Positive Sentiment: VITAS Healthcare was the main growth driver: revenue increased 12.2% to $457.4 million, average daily census rose 9.4%, and adjusted EBITDA excluding Medicare Cap increased 31.4%, with margin expanding 318 basis points to 20.2%. Chemed Reports Third-Quarter 2026 Results
• Positive Sentiment: Management said full-year 2026 adjusted EPS should be at or slightly above the high end of the guidance issued in July, supporting investor confidence in the company’s outlook. Chemed also repurchased 125,000 shares for $66 million during the quarter. Chemed Third-Quarter Revenue Rises
• Neutral Sentiment: Roto-Rooter revenue grew 7.5% to $233.5 million, but the segment’s net income fell 1.8% and adjusted EBITDA declined 2.5%, while its margin contracted 213 basis points to 20.6%. The company also spent approximately $62.5 million reacquiring California franchise territories. Chemed Corporation Reports Earnings Results
• Negative Sentiment: Recent reported insider activity showed nine sales and no purchases over six months, including sales by the CEO and other executives. Although these transactions may be routine, they can add caution around a stock trading near its 52-week high. Chemed Trading Activity

Insider Buying and Selling

In other Chemed news, Director Patrick P. Grace sold 190 shares of the company’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $532.00, for a total value of $101,080.00. Following the completion of the sale, the director directly owned 3,533 shares in the company, valued at approximately $1,879,556. This represents a 5.10% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $539.51, for a total value of $1,079,020.00. Following the completion of the sale, the chief executive officer owned 70,418 shares of the company’s stock, valued at $37,991,215.18. This represents a 2.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 9,190 shares of company stock valued at $4,833,160 over the last quarter. 3.33% of the stock is owned by corporate insiders.

About Chemed

Chemed Corporation (NYSE:CHE) is a Cincinnati, Ohio-based company that provides healthcare and residential and commercial services through two operating businesses: VITAS Healthcare and Roto-Rooter. Its operations serve customers primarily in the United States, with Roto-Rooter also providing services in Canada.

VITAS Healthcare is a provider of hospice and palliative care for individuals with advanced illnesses. The business delivers care in patients’ homes, hospice inpatient units, hospitals, nursing facilities and other care settings.